<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2025-4349</article-id><article-id custom-type="edn" pub-id-type="custom">TMROFA</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-4349</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МНЕНИЕ ПО ПРОБЛЕМЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>OPINION ON A PROBLEM</subject></subj-group></article-categories><title-group><article-title>Злокачественные новообразования и сердечно-сосудистые заболевания: общие патогенетические механизмы и факторы риска. Мнение по проблеме</article-title><trans-title-group xml:lang="en"><trans-title>Cancer and cardiovascular diseases: common pathogenesis pathways and risk factors. A review</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7131-8049</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мамедов</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Mamedov</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мамедов Мехман Ниязи оглы — д.м.н., профессор, руководитель отдела вторичной профилактики ХНИЗ</p><p>Петроверигский пер., д. 10, стр. 3, Москва, 101990</p></bio><bio xml:lang="en"><p>Petroverigsky Lane, 10, bld. 3, Moscow, 101990</p></bio><email xlink:type="simple">mmamedov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7031-7033</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каримов</surname><given-names>А. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Karimov</surname><given-names>A. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>М.н.с. отдела вторичной профилактики хронических неинфекционных заболеваний</p><p>Петроверигский пер., д. 10, стр. 3, Москва, 101990</p></bio><bio xml:lang="en"><p>Petroverigsky Lane, 10, bld. 3, Moscow, 101990</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0307-8252</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сарибекян</surname><given-names>Э. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Saribekyan</surname><given-names>E. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Д.м.н., в.н.с. отделения онкологии и реконструктивно-пластической хирургии молочной железы и кожи</p><p>2-й Боткинский проезд, д. 3, Москва, 125284</p></bio><bio xml:lang="en"><p>2-nd Botkinsky proezd, Moscow, 125284</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6662-5052</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Скопин</surname><given-names>П. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Skopin</surname><given-names>P. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Д.м.н, доцент, директор медицинского института</p><p>Большевистская улица, д. 68, Саранск, Республика Мордовия, 430005</p></bio><bio xml:lang="en"><p>Bol`shevistskaya str., 68, Saransk, Mordovia, 430005</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава России</institution></aff><aff xml:lang="en"><institution>National Medical Research Center for Therapy and Preventive Medicine</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>МНИОИ им. П. А. Герцена — филиал ФГБУ "Национальный медицинский исследовательский центр радиологии" Минздрава России</institution></aff><aff xml:lang="en"><institution>Herzen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Center</institution></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБОУ ВО "Национальный исследовательский Мордовский государственный университет им. Н. П. Огарёва"</institution></aff><aff xml:lang="en"><institution>Ogarev National Research Mordovia State University</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>08</day><month>02</month><year>2026</year></pub-date><volume>24</volume><issue>12</issue><fpage>4349</fpage><lpage>4349</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мамедов М.Н., Каримов А.К., Сарибекян Э.К., Скопин П.И., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Мамедов М.Н., Каримов А.К., Сарибекян Э.К., Скопин П.И.</copyright-holder><copyright-holder xml:lang="en">Mamedov M.N., Karimov A.K., Saribekyan E.K., Skopin P.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/4349">https://cardiovascular.elpub.ru/jour/article/view/4349</self-uri><abstract><p>Цель работы — анализ литературных данных об общих патогенетических механизмах и факторах риска сердечно-сосудистых заболеваний (ССЗ) и злокачественных новообразований (ЗНО). ЗНО являются второй по значимости после ССЗ причиной смерти среди взрослого населения во всем мире. В клинической практике все чаще регистрируется коморбидность ЗНО и ССЗ, что, безусловно, увеличивает риск летальных исходов. Доказано, что основной причиной смерти пациентов с наличием рака молочной железы, предстательной железы или колоректального рака являются заболевания сердца. В то же время, у лиц с ССЗ, особенно с сердечной недостаточностью, повышен риск развития ЗНО. Некоторые патогенетические пути развития ЗНО и ССЗ являются общими. В литературе опубликованы данные о наличии общих генетических мутаций между ЗНО и ССЗ. Важное место в генезе ЗНО и ССЗ занимают хронический воспалительный процесс и окислительный стресс. Многие препараты для химиотерапии усиливают воспалительный процесс, усугубляя существующие ССЗ или способствуют их развитию. Скрининг может быть целесообразным у отдельных категорий выживших пациентов с учетом факторов риска и характером лечения. Необходимо подчеркнуть, что проведения скрининга на предмет ЗНО среди лиц с ССЗ, в частности с сердечной недостаточностью, требует дальнейшего изучения. На фоне мер по профилактике рецидивов ЗНО необходима разработка комплексных мер, направленных на вторичную профилактику коморбидного состояния. Профилактические, диагностические и терапевтические стратегии должны быть частью мультидисциплинарной кардиоонкологической помощи, направленной на улучшение общих результатов.</p></abstract><trans-abstract xml:lang="en"><p>The study aim was to analyze the literature on the common pathogenetic pathways and risk factors for cardiovascular diseases (CVD) and cancer. Cancer is the second leading cause of death among adults worldwide after CVD. In clinical practice, the comorbidity of cancer and CVD is increasingly being recorded, which undoubtedly increases the mortality risk. CVD is the leading cause of death in patients with breast, prostate, or colorectal cancer. At the same time, individuals with CVD, particularly heart failure, have an increased risk of cancer. Some pathogenic pathways in the development of cancer and CVD are common. There are published data on common genetic mutations between cancer and CVD. Chronic inflammation and oxidative stress play a significant role in the genesis of cancer and CVD. Many chemotherapy agents increase inflammation, aggravating prior CVD or promoting its development. Screening may be appropriate in certain categories of surviving patients, taking into account risk factors and the nature of treatment. It is noteworthy that screening for cancer in individuals with CVD, particularly heart failure, requires further study. In the context of measures to prevent cancer recurrence, comprehensive measures aimed at secondary prevention of comorbid conditions should be developed. Preventive, diagnostic, and therapeutic strategies should be part of multidisciplinary cardio-oncology care aimed at improving outcomes.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>злокачественные новообразования</kwd><kwd>сердечнососудистые заболевания</kwd><kwd>факторы риска</kwd><kwd>патогенетические механизмы</kwd><kwd>кардиотоксичность</kwd><kwd>скрининг</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cancer</kwd><kwd>cardiovascular diseases</kwd><kwd>risk factors</kwd><kwd>pathogenetic pathways</kwd><kwd>cardiotoxicity</kwd><kwd>screening</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в рамках госзадания ФГБУ "НМИЦ ТПМ" Минздрава России № 124013100901-6 "Автоматическое определение кальциноза артерий молочной железы на цифровых маммограммах для выявления женщин с вероятностью сердечно-сосудистых и других хронических неинфекционных заболеваний при проведении маммографии"</funding-statement><funding-statement xml:lang="en">This work was carried out within the state assignment of the National Medical Research Center for Therapy and Preventive Medicine № 124013100901-6 "Automated detection of   breast artery calcification on digital mammograms to identify women with a risk of cardiovascular and other noncommunicable diseases during mammography"</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Gigante B, Langley RE, Rocca B. Cancer and cardiovascular diseases: the long, winding and crossing roads. Eur J Prev Cardiol. 2023;30(18):2015-7. doi:10.1093/eurjpc/zwad294.</mixed-citation><mixed-citation xml:lang="en">Gigante B, Langley RE, Rocca B. Cancer and cardiovascular diseases: the long, winding and crossing roads. Eur J Prev Cardiol. 2023;30(18):2015-7. doi:10.1093/eurjpc/zwad294.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Stolfo D, Savarese G. Association between heart failure and cancer: is gender the answer? Eur J Heart Fail. 2021;23(10):1722-4. doi:10.1002/ejhf.2261.</mixed-citation><mixed-citation xml:lang="en">Stolfo D, Savarese G. Association between heart failure and cancer: is gender the answer? Eur J Heart Fail. 2021;23(10):1722-4. doi:10.1002/ejhf.2261.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Pfeffer TJ, Pietzsch S, Hilfiker-­Kleiner D. Common genetic predis­po­sition for heart failure and cancer. Herz. 2020;45(7):632-6. doi:10.1007/s00059-020-04953-9.</mixed-citation><mixed-citation xml:lang="en">Pfeffer TJ, Pietzsch S, Hilfiker-­Kleiner D. Common genetic predis­po­sition for heart failure and cancer. Herz. 2020;45(7):632-6. doi:10.1007/s00059-020-04953-9.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ча­зова И. Е., Виценя М. В., Агеев Ф. Т. Сердечно-­сосудистые ­осложнения противоопухолевой терапии. Москва, М. Гарант, 2019. c. 160. ISBN: 978-5-906456-44-1.</mixed-citation><mixed-citation xml:lang="en">Chazova IE, Vitsenya MV, Ageev FT. Cardiovascular complications of antitumor therapy. Moscow, M. Garant, 2019. p. 225. (In Russ.) ISBN: 978-5-906456-44-1.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ahn Y, Jung MH. Cardiovascular health is the essential but over­looked aspect in the management of cancer survivors. Eur J Prev Cardiol. 2022;29(18):2322-3. doi:10.1093/eurjpc/zwac241.</mixed-citation><mixed-citation xml:lang="en">Ahn Y, Jung MH. Cardiovascular health is the essential but over­looked aspect in the management of cancer survivors. Eur J Prev Cardiol. 2022;29(18):2322-3. doi:10.1093/eurjpc/zwac241.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Васюк Ю. А., Гендлин Г. Е., Емели­на Е. И. и др. Согласованное мнение Российских экспертов по профилактике, диагностике и лечению сердечно-­сосудистой токсичности противоопухолевой терапии. Российский кардио­логический журнал. 2021;26(9):4703. doi:10.15829/1560-4071-2021-4703.</mixed-citation><mixed-citation xml:lang="en">Vasyuk YuA, Gendlin GE, Emelina EI, et al. Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of car­dio­toxicity of anticancer therapy. Russian Journal of Cardio­logy. 2021;26(9):4703. (In Russ.) doi:10.15829/1560-4071-2021-4703.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Dongchen X, Tongyi L, Xueping M, et al. Risk of mortality and other adverse outcomes from myocardial infarction in cancer survivors: a meta-analysis. Int J Clin Oncol. 2023;28(1):41-51. doi:10.1007/s10147-022-02276-9.</mixed-citation><mixed-citation xml:lang="en">Dongchen X, Tongyi L, Xueping M, et al. Risk of mortality and other adverse outcomes from myocardial infarction in cancer survivors: a meta-analysis. Int J Clin Oncol. 2023;28(1):41-51. doi:10.1007/s10147-022-02276-9.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Florido R, Daya NR, Ndumele CE, et al. Cardiovascular Disease Risk Among Cancer Survivors: The Atherosclerosis Risk In Communities (ARIC) Study. J Am Coll Cardiol. 2022;80(1):22-32. doi:10.1016/j.jacc.2022.04.042.</mixed-citation><mixed-citation xml:lang="en">Florido R, Daya NR, Ndumele CE, et al. Cardiovascular Disease Risk Among Cancer Survivors: The Atherosclerosis Risk In Communities (ARIC) Study. J Am Coll Cardiol. 2022;80(1):22-32. doi:10.1016/j.jacc.2022.04.042.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang S, Liu L, Shi S, et al. Bidirectional Association Between Car­diovascular Disease and Lung Cancer in a Prospective Cohort Study. J Thorac Oncol. 2024;(1):80-93. doi:10.1016/j.jtho.2023.09.004.</mixed-citation><mixed-citation xml:lang="en">Zhang S, Liu L, Shi S, et al. Bidirectional Association Between Car­diovascular Disease and Lung Cancer in a Prospective Cohort Study. J Thorac Oncol. 2024;(1):80-93. doi:10.1016/j.jtho.2023.09.004.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Mamedov MN, Badeynikova KK, Karimov AK. Common risk factors and comorbidity of cardiovascular diseases and cancer. Cancer Screen Prev. 2024;3(1):72-4. doi:10.14218/CSP.2023.00044.</mixed-citation><mixed-citation xml:lang="en">Mamedov MN, Badeynikova KK, Karimov AK. Common risk factors and comorbidity of cardiovascular diseases and cancer. Cancer Screen Prev. 2024;3(1):72-4. doi:10.14218/CSP.2023.00044.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Cuomo A, Pirozzi F, Attanasio U, et al. Cancer Risk in the Heart Fai­lu­re Population: Epidemiology, Mechanisms, and Clinical Imp­li­cations. Curr Oncol Rep. 2020;23(1):7. doi:10.1007/s11912-020-00990-z.</mixed-citation><mixed-citation xml:lang="en">Cuomo A, Pirozzi F, Attanasio U, et al. Cancer Risk in the Heart Fai­lu­re Population: Epidemiology, Mechanisms, and Clinical Imp­li­cations. Curr Oncol Rep. 2020;23(1):7. doi:10.1007/s11912-020-00990-z.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Koelwyn GJ, Newman AAC, Afonso MS, et al. Myocardial infarction accelerates breast cancer via innate immune reprogramming. Nat Med. 2020;26(9):1452-8. doi:10.1038/s41591-020-0964-7.</mixed-citation><mixed-citation xml:lang="en">Koelwyn GJ, Newman AAC, Afonso MS, et al. Myocardial infarction accelerates breast cancer via innate immune reprogramming. Nat Med. 2020;26(9):1452-8. doi:10.1038/s41591-020-0964-7.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Prousi GS, Joshi AM, Atti V, et al. Vascular Inflammation, Cancer, and Cardiovascular Diseases. Curr Oncol Rep. 2023;25(9):955-63. doi:10.1007/s11912-023-01426-0.</mixed-citation><mixed-citation xml:lang="en">Prousi GS, Joshi AM, Atti V, et al. Vascular Inflammation, Cancer, and Cardiovascular Diseases. Curr Oncol Rep. 2023;25(9):955-63. doi:10.1007/s11912-023-01426-0.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Camilli M, Iannaccone G, La Vecchia G, et al. Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases. Expert Rev Hematol. 2021;14(6):537-46. doi:10.1080/17474086.2021.1943353.</mixed-citation><mixed-citation xml:lang="en">Camilli M, Iannaccone G, La Vecchia G, et al. Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases. Expert Rev Hematol. 2021;14(6):537-46. doi:10.1080/17474086.2021.1943353.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Neufeldt D, Cushman S, Bär C, et al. Circular RNAs at the inter­sec­tion of cancer and heart disease: potential therapeutic targets in cardio-­oncology. Cardiovasc Res. 2023;119(7):1495-508. doi:10.1093/cvr/cvad013.</mixed-citation><mixed-citation xml:lang="en">Neufeldt D, Cushman S, Bär C, et al. Circular RNAs at the inter­sec­tion of cancer and heart disease: potential therapeutic targets in cardio-­oncology. Cardiovasc Res. 2023;119(7):1495-508. doi:10.1093/cvr/cvad013.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Tocchetti CG, Ameri P, de Boer RA, et al. Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-­oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovasc Res. 2020;116(11):1820-34. doi:10.1093/cvr/cvaa222.</mixed-citation><mixed-citation xml:lang="en">Tocchetti CG, Ameri P, de Boer RA, et al. Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-­oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovasc Res. 2020;116(11):1820-34. doi:10.1093/cvr/cvaa222.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О. М., Концевая А. В., Ка­ли­нина А. М. и др. Коморбидность пациентов с хроническими неинфекционными заболеваниями в практике врача-­терапевта. Евразийское руководство. Кардиоваскулярная терапия и профилактика. 2024;23(3):3996. doi:10.15829/1728-8800-2024-3996.</mixed-citation><mixed-citation xml:lang="en">Drapkina OM, Kontsevaya AV, Kalinina AM, et al. Comorbidity of pa­tients with noncommunicable diseases in general practice. Eur­asian guidelines. Cardiovascular Therapy and Prevention. 2024;23(3): 3996. (In Russ.) doi:10.15829/1728-8800-2024-3996.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Velusamy R, Nolan M, Murphy A, et al. Screening for Coronary Artery Di­sease in Cancer Survivors: JACC: CardioOncology State-of-the-­Art Review. JACC CardioOncol. 2023;5(1):22-38. doi:10.1016/j.jaccao.2022.12.007.</mixed-citation><mixed-citation xml:lang="en">Velusamy R, Nolan M, Murphy A, et al. Screening for Coronary Artery Di­sease in Cancer Survivors: JACC: CardioOncology State-of-the-­Art Review. JACC CardioOncol. 2023;5(1):22-38. doi:10.1016/j.jaccao.2022.12.007.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И. Е., Агеев Ф. Т., Аксе­нова А. В. и др. Евразийские клинические рекомендации по диагностике, профилактике и лечению сердечно-­сосудистых осложнений при противоопухолевой терапии (2022). Евразийский кардиологический журнал. 2022;(1):6-79. doi:10.38109/2225-1685-2022-1-6-79.</mixed-citation><mixed-citation xml:lang="en">Chazova IE, Ageev FT, Aksenova AV, et al. Eurasian clinical guidelines for the diagnosis, prevention and treatment of cardiovascular complications during antitumor therapy (2022). Eurasian Journal of Cardiology. 2022;(1):6-79. (In Russ.) doi:10.38109/2225-1685-2022-1-6-79.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ва­сюк Ю. А., Шупенина Е. Ю., Новосел Е. О. и др. Возможности пер­вичной медикаментозной профилактики кардиотоксичности противоопухолевой терапии у онкологических больных. Рос­сийский кардиологический журнал. 2022;27(12):5258. doi:10.15829/1560-4071-2022-5258.</mixed-citation><mixed-citation xml:lang="en">Vasyuk YuA, Shupenina EY, Novosel EO, et al. Potential of primary drug prevention of cardiotoxicity in the context of anticancer therapy. Russian Journal of Cardiology. 2022;27(12):5258. (In Russ.) doi:10.15829/1560-4071-2022-5258.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Кулиева А. А., Еме­ли­на Е. И., Гендлин Г. Е. и др. Сердечно-­сосудистые ослож­не­ния терапии ингибиторами контрольных точек иммунитета. Качественная клиническая практика. 2019;(4):55-65. doi:10.1016/2588-0519-2019-4-55-65.</mixed-citation><mixed-citation xml:lang="en">Kulieva AA, Emelina EI, Gendlin GE, et al. Cardiovascular com­pli­ca­tions of therapy with immune checkpoint inhibitors. High-qua­li­ty clinical practice. 2019;(4):55-65. (In Russ.) doi:10.1016/2588-0519-2019-4-55-65.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Федоткина Ю. А., Пан­чен­ко Е. П. Тромбозы в онкологии. Часть 2. Атеротромбоз. 2017;(3):3-12.</mixed-citation><mixed-citation xml:lang="en">Fedotkina YuA, Panchenko EP. Thrombosis in oncology. Part 2. Athe­ro­throm­bosis. 2017;(3):3-12. (In Russ.)</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
